Everolimus, Whole Blood
Use
Everolimus is a proliferation signal inhibitor that prevents allograft rejection. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T cells, which is driven by T-cell-specific interleukins. Everolimus inhibits an intracellular signaling pathway that is triggered up binding of these T-cell growth factors to their respective receptors, and which normally leads to cell proliferation. The blockage of this signal by everolimus leads to an arrest of the cells at the G1 stage of cell cycle.
Special Instructions
Trough levels are most reproducible for patient preparation. Ensure specimen collection in lavender-top (EDTA) tube to meet requirements.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration, limiting its scope to results without FDA approval. The assay is not intended to diagnose diseases outside the intended use in monitoring Everolimus levels.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 50544-6
- 50544-6
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2 mL
Minimum Volume
0.5 mL
Container
Lavender-top (EDTA) tube
Patient Preparation
Trough levels are most reproducible.
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |